In its first year of use in the United States, the overall estimated effectiveness of the respiratory syncytial virus (RSV) vaccine against respiratory illness and severe disease in adults aged 60 years and older was 92%, a team led by…
RSV vaccine for older adults 92% protective against poor outcomes, real-world study estimates
